Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Tuesday

Key Points

• May 5 after-market: Day One will report Q1 2026 results after the close on Tuesday, May 5 (earnings call 4:30 PM ET); analysts project EPS of ($0.31) and revenue of $54.35M.
• In the prior quarter the company missed EPS (reported ($0.21) vs. estimate ($0.17)) but beat revenue at $53.72M; analysts forecast about -$1 EPS for the current fiscal year and the consensus rating is "Hold" with a $23.29 price target.
• Insiders have been net sellers (36,461 shares worth roughly $423K in three months) while institutional investors own ~87.95%; Day One's market cap is about $2.22B and its 52‑week range is $5.64–$21.53.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) is anticipated to post its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Day One Biopharmaceuticals to post earnings of ($0.31) per share and revenue of $54.35 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). The company had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. On average, analysts expect Day One Biopharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Day One Biopharmaceuticals Stock Performance

DAWN opened at $21.53 on Tuesday. The company has a market cap of $2.22 billion, a PE ratio of -20.90 and a beta of -1.74. The stock has a 50-day moving average of $18.83 and a 200-day moving average of $12.67. Day One Biopharmaceuticals has a 52-week low of $5.64 and a 52-week high of $21.53.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 6,065 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $70,354.00. Following the completion of the sale, the chief financial officer owned 312,025 shares in the company, valued at approximately $3,619,490. This trade represents a 1.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Lauren Merendino sold 5,814 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $67,442.40. Following the completion of the sale, the insider owned 60,157 shares of the company's stock, valued at $697,821.20. This represents a 8.81% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Day One Biopharmaceuticals

Hedge funds have recently modified their holdings of the company. Quarry LP acquired a new position in shares of Day One Biopharmaceuticals in the 3rd quarter worth approximately $49,000. Prudential Financial Inc. acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter worth approximately $69,000. Lazard Asset Management LLC acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter worth approximately $89,000. LPL Financial LLC acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $102,000. Finally, Virtus Advisers LLC acquired a new position in shares of Day One Biopharmaceuticals in the 4th quarter worth approximately $104,000. Institutional investors own 87.95% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. HC Wainwright reaffirmed a "neutral" rating and issued a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 10th. JonesTrading downgraded Day One Biopharmaceuticals from a "buy" rating to a "hold" rating and lifted their price target for the stock from $20.00 to $21.50 in a research report on Friday, March 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Day One Biopharmaceuticals in a research report on Monday, December 29th. TD Cowen downgraded Day One Biopharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, March 6th. Finally, Wedbush reaffirmed a "neutral" rating and issued a $21.50 price target (down from $30.00) on shares of Day One Biopharmaceuticals in a research report on Monday, March 9th. One equities research analyst has rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of "Hold" and a consensus price target of $23.29.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc NASDAQ: DAWN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company's pipeline includes several small-molecule candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.